A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...